Dosing in the Phase 3 Diabetes Trial (TRANSCEND-T2D-1) A1C reduction: -1.7% to -2.0% across doses (from baseline 7-9.5%) Weight loss at 12 mg: 16.8% (-36.6 lbs) at 40 weeks Discontinuation due to adverse events was relatively low across all doses, similar to the patterns seen in TRIUMPH-4 The diabetes population typically loses less weight on GLP-1 drugs than the obesity-only population, which is consistent with what was observed: ~17% weight loss in T2D vs
That is a minuscule amount of liquid, barely a droplet, and extremely difficult to measure accurately on a standard insulin syringe
The authors speculated that increased GSH reflected a compensatory response to ongoing inflammatory processes related to brain injury
Contributor Hope Ricciotti, MD, Editor at Large, Harvard Women's Health Watch Disclaimer: As a service to our readers, Harvard Health Publishing provides access to our library of archived content
Another key reason for the avalanche of praise is Moringa Magics simplicity